DARE BIOSCIENCE, INC.
DARE-HPV, a vaginal insert combining lopinavir and ritonavir to treat persistent high-risk HPV infections
- Sector
- Biotech
- Headquarters
- SAN DIEGO, CA
- Founded
- 2005
- Latest Form D
- $12.4M, Aug 2026
- Total capital
- $105M
- Federal grants
- $7.2M
- 11 awards · 2018–2026
- Rank in peer group#4 of 18
- Private capital raised
- $98.2M
- 12 Form D · last Aug 2026
- 2 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 4 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 12th filing$12.4M
- Federal grantHealth and Human S · Phase II · A first-in-class product for the clearance of high-risk human papillomaviruses$1M
- Federal grantHealth and Human S · Phase II · A first-in-class product for the clearance of high-risk human papillomaviruses$1M
- Federal grantHealth and Human S · Phase II · A novel intravaginal ring technology featuring the sustained release of natural progesterone for the prevention of preterm birth in at-risk women$1M
- Offering registeredForm D · SEC · 11th filing$15M
- Private capital raisedForm D · SEC · 10th filing$1.7M
- Federal grantHealth and Human S · Phase II · A novel intravaginal ring technology featuring the sustained release of natural progesterone for the prevention of preterm birth in at-risk women$992K
- Private capital raisedForm D · SEC · 9th filing$2.4M
- Private capital raisedForm D · SEC · 8th filing$20.7M
- Private capital raisedForm D · SEC · 7th filing$1
- Private capital raisedForm D · SEC · 6th filing$13M
- Private capital raisedForm D · SEC · 5th filing$15M
- Private capital raisedForm D · SEC · 4th filing$16.5M
- Private capital raisedForm D · SEC · 3rd filing$1.5M
- Private capital raisedForm D · SEC · 2nd filing$5M
- Private capital raisedForm D · SEC · 1st filing$10M
Show 7 earlier federal awards
- Federal grantHealth and Human S · Phase I · Therapeutic targeting of FKBP51 for the prevention of stress-induced preterm birth$385K
- Federal grantHealth and Human S · Phase I · Defining end-user preferences among US women to optimize the design of a long-acting injectable hormonal contraceptive$249K
- Federal grantHealth and Human S · Phase I · Subcutaneous insertion and removal of a user-controlled, long-acting, and reversible contraceptive device$310K
- Federal grantHealth and Human S · Phase II · A novel intravaginal ring technology featuring the sustained release of natural progesterone for the prevention of preterm birth in at-risk women$300K
- Federal grantHealth and Human S · Phase II · Safety, and acceptability of a non-hormonal vaginal ring$731K
- Federal grantHealth and Human S · Phase II · Safety, and acceptability of a non-hormonal vaginal ring$983K
- Federal grantHealth and Human S · Phase II · Safety, and acceptability of a non-hormonal vaginal ring$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 18 peers
Line = medianBiotech · Device
- Federal grants#4 · top 22%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Cheryl R. BlanchardDirectorNamed in SEC Form D filings
- Gregory W. MatzDirectorNamed in SEC Form D filings
- Jessica D. GrossmanDirectorNamed in SEC Form D filings
- Lisa Martucci Walters-HoffertExecutive OfficerNamed in SEC Form D filings
- MarDee Martucci Haring-LaytonExecutive OfficerNamed in SEC Form D filings
- Robin J. SteeleDirectorNamed in SEC Form D filings
Show all 11 people
- Roger L. HawleyDirectorNamed in SEC Form D filings
- Sabrina Martucci JohnsonExecutive Officer, DirectorNamed in SEC Form D filings
- Sophia N. Ononye-OnyiaDirectorNamed in SEC Form D filings
- Susan L. KelleyDirectorNamed in SEC Form D filings
- William H. RastetterDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 4- PendingCompositions And Methods Of Treating Female Sexual Arousal DisorderUSPTOApplication 63484812
- PendingCompositions And Methods For Treating DysmenorrheaUSPTOApplication 63481415
- PendingMethods And Devices For Hormone Replacement TherapyUSPTOApplication 63437940
Show all 4 patent records
- Compositions And Methods Of Treating Female Sexual Arousal DisorderApplication 63484812Pending
- Compositions And Methods For Treating DysmenorrheaApplication 63481415Pending
- Methods And Devices For Hormone Replacement TherapyApplication 63437940Pending
- Systems And Methods For Treatment Of Bacterial Vaginosis And Other IndicationsApplication PCTUS2022038201Pending
Related companies, and why
- ZENOPHARM, LLCSimilar federal contract value in Biotech · null in contracts
- OMNIOX INCSimilar federal contract value in Biotech · null in contracts
- IMMUSOFT CORPSimilar federal contract value in Biotech · null in contracts
- Ventus TherapeuticsSimilar federal contract value in Biotech · null in contracts
- TFF PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- ACURASTEM INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .